Novo Nordisk price cuts set to shake up India’s GLP-1 market, challenge generics

Novo Nordisk is slashing prices for its diabetes and weight loss drugs Ozempic and Wegovy in India. This move aims to make these treatments more accessible to patients. Industry experts believe this will significantly impact competition. Novo Nordisk's established reputation with doctors is also expected to help. The company hopes to gain a larger share of the GLP-1 market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jJXkrHD
via IFTTT